Tal Zvi Zaks Sells 5,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Tal Zvi Zaks sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $129.71, for a total value of $648,550.00. Following the completion of the sale, the insider now owns 5,000 shares of the company’s stock, valued at $648,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tal Zvi Zaks also recently made the following trade(s):

  • On Monday, March 22nd, Tal Zvi Zaks sold 1,199 shares of Moderna stock. The shares were sold at an average price of $144.82, for a total value of $173,639.18.
  • On Monday, March 15th, Tal Zvi Zaks sold 10,034 shares of Moderna stock. The shares were sold at an average price of $140.68, for a total value of $1,411,583.12.
  • On Monday, January 25th, Tal Zvi Zaks sold 5,000 shares of Moderna stock. The shares were sold at an average price of $143.12, for a total value of $715,600.00.
  • On Tuesday, January 19th, Tal Zvi Zaks sold 5,000 shares of Moderna stock. The stock was sold at an average price of $123.88, for a total value of $619,400.00.

MRNA stock opened at $131.47 on Thursday. The company has a current ratio of 2.43, a quick ratio of 2.43 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $52.66 billion, a PE ratio of -81.15, a P/E/G ratio of 0.53 and a beta of 1.73. Moderna, Inc. has a 12-month low of $31.32 and a 12-month high of $189.26. The business’s fifty day moving average price is $142.99 and its 200 day moving average price is $120.18.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.44). The firm had revenue of $570.80 million during the quarter, compared to analysts’ expectations of $279.41 million. Moderna had a negative net margin of 242.73% and a negative return on equity of 28.11%. Moderna’s quarterly revenue was up 3948.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) EPS. Research analysts predict that Moderna, Inc. will post -1.5 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. tru Independence LLC purchased a new stake in shares of Moderna in the 4th quarter valued at $19,849,000. Black Swift Group LLC purchased a new stake in Moderna during the 4th quarter worth about $26,000. Catalyst Capital Advisors LLC purchased a new stake in Moderna during the 4th quarter worth about $29,000. Clearview Wealth Advisors LLC purchased a new stake in Moderna during the 4th quarter worth about $32,000. Finally, Park Capital Group purchased a new stake in Moderna during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 51.21% of the company’s stock.

MRNA has been the topic of a number of research analyst reports. Chardan Capital lifted their price target on Moderna from $107.00 to $182.00 and gave the stock a “buy” rating in a research note on Monday, March 8th. Barclays lifted their price target on Moderna from $169.00 to $178.00 in a research note on Friday, February 26th. Bank of America reaffirmed a “sell” rating and issued a $140.00 price target on shares of Moderna in a research note on Friday, February 26th. Brookline Capital Management lifted their price target on Moderna from $180.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, March 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $139.00 price target on shares of Moderna in a research note on Friday, December 11th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $150.56.

Moderna Company Profile

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Recommended Story: History of the Euro STOXX 50 Index

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.